ADVERTISEMENTREMOVE AD

Intas Develops New Hyperimmune Globulin For COVID-19 Treatment

Published
Coronavirus
2 min read
story-hero-img
i
Aa
Aa
Small
Aa
Medium
Aa
Large
Hindi Female

The Research and Development team of Ahmedabad-based Intas Pharmaceuticals has developed a COVID-19 specific Hyperimmune Globulin as treatment for patients suffering from moderate to severe infection. According to a press release published in CISION, Hyperimmune Globulin can also be employed as prophylaxis for frontline workers who come in close contact with COVID-19 patients.

The new treatment could serve as a useful therapeutic technique against the viral disease until a vaccine becomes available. Intas is among the world's first pharmaceutical firms to adopt this approach towards the treatment of COVID-19.

The Drug Controller General of India (DCGI) has granted approval for the conduction of clinical trials for the newly developed Hyperimmune Globulin. Once its efficacy and safety are established in the trials, the product will be available for the treatment of COVID-19 patients.

“This endeavour is a testament to Intas’ commitment towards meeting unmet medical need of the society through research driven solutions.”
Dr Alok Chaturvedi, Head of Medical & Regulatory Affairs, Intas

This therapeutic innovation will be part of the company’s Corporate Social Responsibility (CSR) initiative. The firm will collaborate with Indian blood banks for the development of the treatment technique, which will enable the procurement of convalescent plasma (plasma extracted from patients recovered from COVID-19 infection).

ADVERTISEMENTREMOVE AD

Hyperimmune Globulin will provide a purified and enriched preparation of COVID-19 specific neutralizing antibodies in high concentration, free from blood-transmitted viruses and other plasma proteins, said Dr Suma Ray, Vice President and Head of Plasma Operations at Intas. Hyperimmune Globulin will permit consistent and precise dosing, and a predictable response early on in the treatment of COVID-19.

The product does not entail donor selection or blood group matching. It is a specialised antibody treatment, which unlike plasma therapy, can be easily administered to patients even in the remotest parts of the country.

In order to obtain convalescent plasma, Intas is looking to collaborate with medical institutions and blood donation groups. The company is also set to launch a website, which will help recovered COVID-19 patients locate their nearest blood bank where they can safely donate their plasma.

Intas is seeking government aid to enable the supply of convalescent plasma. This will help facilitate the manufacturing of Hyperimmune Globulin and thereby help more patients overcome COVID-19.

(With inputs from CISION)

(At The Quint, we are answerable only to our audience. Play an active role in shaping our journalism by becoming a member. Because the truth is worth it.)

0

Read Latest News and Breaking News at The Quint, browse for more from fit and coronavirus

Topics:  Treatment   coronavirus   COVID-19 

Speaking truth to power requires allies like you.
Become a Member
3 months
12 months
12 months
Check Member Benefits
Read More
×
×